A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of HRS9531injection in Healthy Subjects and Subjects With Impaired Renal Function
Latest Information Update: 08 Mar 2024
At a glance
- Drugs HRS 9531 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 05 Mar 2024 Status changed from not yet recruiting to recruiting.
- 12 Feb 2024 New trial record